521 AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studiesTingting Zhong, Min Jing, Xinghua Pang et al.|Regular and Young Investigator Award Abstracts|2022Cited by 18